A key active ingredient in TPR20 is the compound Lidocaine.
Lidocaine - A Profile
Lidocaine has been delivering safe, topical, anesthesia and pain relief to generations of patients going to the dentist as the ingredient in “numbing gel.” In the 1940’s this Swedish invention began to completely replace Nitrous Oxide gas and Novocain in dentistry. As both a topical and injectable it has been minimizing the discomfort of all our dental experiences for over 60 years in safety.
Lidocaine belongs to a class of compounds called amides. The most common amides found in nature are proteins. Amides include Nicotinamide, vitamin B3. Another natural amide is urea which is important in Kidney function, balancing water levels, blood pressure and sodium levels in the body.
The rapid pain relief delivered by Lidocaine reduces the neurobiological stresses that aggravate inflammation. Autonomic and sensory nerves, especially the peripheral C fibers which transmit pain, are closely linked to inflammatory cells in the human body, in particular Mast cells. Pain is therefore a trigger leading to the release of inflammatory mediators, histamine, cytokines and interleukins. In TPR20 the neurological inhibition of pain by Lidocaine is supported by an array of specific, natural, anti-inflammatory, anti-oxidant and healing support compounds.
Lidocaine. Seventy safe years in dentistry.
It is important to distinguish Lidocaine from other anesthetics with similar names such as Cocaine and Novocain. These are Esters, a chemical group which is highly allergic and no longer used in dentistry. Lidocaine, which is NOT an Ester, has the advantage of being non-allergic. There appears to be no documented allergic reaction to Lidocaine that contained no preservatives. Dentists, the main users of Lidocaine, see almost no allergic reactions even to injectable anesthetic using the compound. If there is one, it is likely to be the preservative used to stabilize the vasoconstrictor used to complement the Lidocaine injections.
Lidocaine. Method of action
Lidocaine has a very different action from most pain medication. Drugs such as Aspirin or other over the counter Non Steroidal Anti-Inflammatory Drugs (NSAIDs) are essentially anti-inflammatories. They have no direct action on pain transmission. Lidocaine stabilizes the nerve membranes that transmit pain. This temporary stabilization decreases sodium influx across the nerve cell membrane and inhibits the release of pain signals. As such Lidocaine is a true anesthetic.
It is more effective at inhibiting pain fibers than other sensory nerves and as such is very specific. Lidocaine is also rapidly transmitted across the skin. Its effect is felt before an oral tablet has even begun to dissolve in the stomach.
Lidocaine. Topical Safety
The literature on Lidocaine rarely distinguishes between topical and injectable applications. When used as an injectable the action becomes systemic. When used topically the action is limited to the local area on which it is applied. The Miami study, specifically focused on Lidocaine as a topical application. The study reported on the application of 30 and 60 grams of a 4% lidocaine cream. This is 60 to 120 times the Lidocaine present in a single dose of TPR20. Blood tests were done prior to the application and at 1 hour, 2 hours, 6 hours, and 24 hours afterwards. The volunteers were assessed for any clinical signs of lidocaine toxicity. All blood samples showed less than 0.5 mcg/mL of Lidocaine in the blood. Patients reported no systemic effects and did not show any clinical signs of lidocaine toxicity. Conclusions were that large doses of occluded 4% lidocaine cream were safe; the test subjects showed no evidence of clinical toxicity and blood levels showed no evidence of significant lidocaine or lidocaine metabolites.
Lidocaine is also used in Veterinary medicine where non-invasive studies show no adverse reaction in either dogs, horses or the sensitive metabolism of cats.
There are some instances of an individual who develops a temporary itching reaction to Lidocaine. These are rare and disappear rapidly.
Andreoni V. Giorgi M. Evaluation of Plasma Detectable Concentrations of Two Lidocaine Transdermal Formulations and Their Analgesic Effect in the Horse. Journal of Equine Vetinary Science. Volume 29, Issue 9, Pages 681-686 (September 2009).
Fransson BA. et. al. Transdermal absorption of a liposome-encapsulated formulation of lidocaine following topical administration in cats. Am J Vet Res. 2002 Sep;63(9):1309-12.
Jeff Ko, et al. Plasma Concentrations of Lidocaine in Dogs Following Lidocaine Patch Application. Journal of the American Animal Hospital Association 43:280-283 (2007).
Nestor MS. Safety of occluded 4% liposomal lidocaine cream. J Drugs Dermatol. 2006 Jul-Aug;5(7):618-20.
Related article title
Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Proin ipsum odio, luctus in vehicula tempor, bibendum at nisl. Proin in facilisis mauris, vitae iaculis felis. Etiam auctor quis tellus quis laoreet. Fusce pretium ex at posuere viverra.
Related article title
Proin in facilisis mauris, vitae iaculis felis. Etiam auctor quis tellus quis laoreet. Fusce pretium ex at posuere viverra. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Aenean in est nec justo lobortis vestibulum eget vel mauris.
Related article title
Duis vel diam tortor. Curabitur iaculis porttitor ante, at dictum nibh volutpat sit amet. Nullam eu quam ac lacus posuere lacinia. Ut interdum dolor et quam dictum, at rhoncus magna commodo. Aliquam tempus ex tristique mi ullamcorper tristique. Praesent vitae vehicula mi. Praesent tempus leo elit, non condimentum mauris vulputate non.